Pegaspargase, a modified version of the enzyme L-asparaginase, is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL). Gennova launched a generic/biosimilar pegaspargase under the brand name Hamsyl^® as a single vial of 3750 IU/5ml (750 IU/ml). Hamsyl^® has been in market since last 5 year and benefited >10,000 patient of ALL in India and other countries. Hamsyl® is one of the leading generic of pegaspargase supported by human clinical data. In few published studies, Hamsyl^® has been found to be safe and efficacious for use in patient of ALL.